|
|
Introducing the RAPAFLO® Promise
The RAPAFLO Promise
Watson is committed to helping patients live better. If RAPAFLO does not meet your needs, we will reimburse up to a $50 copay for the first time you use another prescription treatment (terazosin, doxazosin, tamsulosin, or alfuzosin).
Who is eligible?
- Patients who are new to therapy with RAPAFLO and have paid for 1 month of RAPAFLO therapy and used it as prescribed*
How does the RAPAFLO Promise work?
- Within 60 days of filling the prescription for the competitive product, just request THE RAPAFLO PROMISE materials from your physician's office. You will need to send in the following documentation:
- The signed RAPAFLO Promise Registration Card (from your physician's office)
- Pharmacy receipts for 1 month of RAPAFLO therapy and a 1-month supply of competitor's product. Receipt must show the total out-of-pocket cost for the new prescription and the name of the product being purchased
RAPAFLO is available only by prescription. For patients with no prescription insurance coverage, Watson has created the RAPAFLO patient assistance program for qualifying patients. For more information, please visit http://www.rapaflo.com/how-help-afford.asp
Terms and Conditions
- Patients must be new to therapy with RAPAFLO but could have previously taken a competing
product prior to beginning RAPAFLO therapy
- Patients receiving copay assistance for RAPAFLO are eligible
- Patients must provide proof of 1 paid month of therapy with RAPAFLO, proof of purchase
of competing product, and the card attached to the patient information leaflet
- Offer expires 60 days after the date the prescription for the competitive product
(terazosin, doxazosin, tamsulosin, or alfuzosin) is filled at the pharmacy
- Patients cannot be receiving copay assistance or free product from manufacturer of
competing product
- Total patient reimbursement is limited to $50 or actual out-of-pocket cost, whichever
is lower
- Watson reserves the right to rescind, revoke, or amend this offer without notice
at any time
- Watson will not sell or rent patient’s personal information to others
- This offer is not valid for individuals who are covered on Medicaid, Medicare, TriCare,
or any other state or federal healthcare program
- Not valid for residents of Massachusetts, Rhode Island, or anywhere else prohibited
by law
- Offer good only in the United States and Puerto Rico
- Fenter TC, Naslund MJ, Shah MB, et al. The cost of treating the 10 most prevalent diseases in men 50 years of age or older. Am J Manag Care. 2006;12(4 suppl):S90-S98
- Data on file, Watson Pharma, Inc.
- National Institute of Diabetes and Digestive and Kidney Diseases. Prostate enlargement: benign prostatic hyperplasia. NIH Publication No. 07-3012. June 2006.
- Bruskewitz RC. Quality of life and sexual function in patients with benign prostatic hyperplasia. Rev Urol. 2003;5(2):72-80
- Roberts RO, Jacobsen SJ, Rhodes T, et al. Natural history of prostatism: impaired health status in men with lower urinary tract symptoms. J Urol. 1997;157:1711-1717
- RAPAFLO™ (silodosin) full prescribing information. Corona, CA: Watson Pharma Inc. October 2008.
- Agency for Healthcare Quality and Research (U.S. Dept Health and Human Services): Quick Tips When Talking With Your Doctor. Available at: http://www.ahrq.gov/consumer/quicktips/doctalk.htm.
- American Urological Association. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol. 2003;170:530-547
- Nickel JC. Comparison of clinical trials with finasteride and dutasteride. Rev Urol. 2004;6 Suppl 9:S31-9
- Benign Prostatic Hyperplasia (BPH): A Patient’s Guide. Available at: http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/patient-guides/bph_guide_2003.pdf. Accessed February 4, 2009.
- National Institute on Aging: Talking With Your Doctor. Available at: http://www.nia.nih.gov/HealthInformation/Publications/TalkingWithYourDoctor/. Accessed March 5, 2009.
- Medline Plus Medical Encyclopedia from NIH: Enlarged Prostate. Available at: http://www.nlm.nih.gov/medlineplus/ency/article/000381.htm. Accessed March 5, 2009.
- Shvartzman P, Borkan JM, Stoliar L, et al. Second-hand prostatism: effects of prostatic symptoms on spouses’ quality of life, daily routines and family relationships. Family Pract. 2001;18:610-613.
- Kuritzky L. A primary care physician’s perspective on benign prostatic hyperplasia. Rev Urol. 2003;5(suppl 5):S42-S48.
- Wolters R, et al: Lower urinary tract symptoms: social influence is more important than symptoms in seeking medical care. BJU Int. 2002;90:655–661.
- Rosen RC, Giuliano F, Cason CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 2005;47:824–837.
- Ponholzer A, Madersbacher S. Lower urinary tract symptoms and erectile dysfunction; Links for diagnosis, management and treatment. Int J Impot Res. 2007;19:544-550.
- Straus SM, Kors JA, De Bruin ML, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol. 2006;47:362-367.
- Nomiya M, Yamaguchi O. A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol. 2003;170(2 Pt 1):649-653.
- Murata S, Taniguchi T, Takahashi M, et al. Tissue selectivity of KMD-3213, an alpha(1)-adrenoreceptor antagonist, in human prostate and vasculature. J Urol. 2000;164:578-583.
- Stafford-Smith M, Bartz R, Wilson K, et al. Alpha-adrenergic mRNA subtype expression in the human nasal turbinate. Can J Anesth. 2007;54:549-555.
- Cialis® (tadalafil) full Prescribing Information. Indianapolis IN: Eli Lilly and Co.; June 2007.
- Viagra® (sildenafil) full Prescribing Information. New York, NY: Pfizer Inc. October 2006.
- Levitra® (vardenafil) full Prescribing Information. Kenilworth, NJ: Schering Corporation.
- McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;18:2387-2398
- Issa MM, Regan T. Medical therapy for benign prostatic hyperplasia—present and future impact. Am J Manag Care. 2007;13:S4-S9.
- Wei JT, Calhoun E, Jacobsen SJ. Urologic Diseases in America Project: benign prostatic hyperplasia. J Urol. 2008;179(5 Suppl.):S75-S80.
- Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474.
- Hernández C, Estivill E, Prieto M, et al. Nocturia in Spanish patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). Curr Med Res Opin. 2008;24(4):1033-1038
- Schwinn DA, Roehrborn CG alpha-1 Adrenoreceptor subtypes and lower urinary tract symptoms. Int J Urol. 2008; 15:193-199.
- http://www.dictionary.com
- Atlas of Human Anatomy, Frank H. Netter, MD, Ciba-Geigy Corporation, Summit, NJ, 1989.
|